步长稳心颗粒治疗心律失常的临床研究

Clinical study of wenxinkeli in treatment of cardiac arrhythmia

目的研究稳心颗粒对心律失常的疗效及安全性。方法选取有明显临床症状的心律失常患者120例,随机分为治疗组(60例)给予稳心颗粒口服,9g,3次/d,对照组(60例)给予心律平口服,150mg,3次/d。1个疗程(4周)后,观察用药前后患者临床症状、心律失常的变化及不良反应。结果稳心颗粒对心律失常的总有效率均为83.3%,心律平的总有效率分别为85%,两者差异无统计学意义(P>0.05);治疗组的不良反应发生率为3.33%,对照组为11.7%,差异有统计学意义(P<0.05)。结论稳心颗粒对心律失常的疗效与心律平相当,其不良反应发生率低于心律平。

Objective To study the antiarrythmia effect and safety of Wenxinkeli for the patients with cardiac arrhythmia.Methods 120 patients with cardiac arrhythmia,randomized divided into two groups,the treating group(n=60)taken Wenxinkeli 9 g tid for 4 weeks,the control group(n=60)taken propafenone 150mg tid for 4 weeks.Then the effect of cardiac arrhythmia,symptoms and adverse effects were observed.Results The total effective rate of the treating group is 83.3%,the total effective rate of the control group is 85%.The antiarrhythmia effects of Wenxinkeli for cardiac arrhythmia were as same as that of propafenone(P>0.05),adverse effects were significantly less than that of propafenone(P<0.05).Conclusion Wenxinkeli is effective and safe for cardiac arrhythmia.